ESR1 Gene Status Correlates with Estrogen Receptor Protein Levels Measured by Ligand Binding Assay and Immunohistochemistry

Overview

Journal Mol Oncol

Specialties Molecular Biology
Oncology

Date 2012 May 26

PMID 22626971

Citations 12

Authors

Anne-Vibeke Laenkholm

Ann Knoop

Bent Ejlertsen

Tine Rudbeck

Maj-Britt Jensen

Sven Muller

Anne Elisabeth Lykkesfeldt

Birgitte Bruun Rasmussen

Kirsten Vang Nielsen

Affiliations

Soon will be listed here.

Abstract

The Estrogen Receptor (ER) is an established predictive marker for the selection of adjuvant endocrine treatment in early breast cancer. During the 1990s Immunohistochemistry (IHC) replaced cytosol based assays for determination of ER status. This study examined the association between ER protein level determined by two different methods and ESR1 gene copy number. From 289 primary high-risk breast cancer patients, randomized in the Danish Breast Cancer Cooperative Group (DBCG) 77C trial, results from cytosolic ER levels were available from ligand binding assays. Archival tumor tissue was retrieved from 257 patients. ESR1/CEN-6 ratio was analyzed successfully by Fluorescence In Situ Hybridization (FISH) in 220 (86%) patients. ESR1 amplification (ESR1/CEN-6 ≥ 2.00) was observed in 23% of the patients and ESR1 deletion (ESR1/CEN-6 < 0.80) was observed in 32%. Further, we identified ESR1 gain (ratio ESR1/CEN-6 from 1.30 to 1.99) in 19% of the patients. A positive correlation of ESR1 FISH with both ER-cytosol and ER IHC was found (p < 0.0001). Amplification and gain of the ESR1 gene are associated with higher ER protein content measured by ligand binding assay and a more intense nuclear staining by IHC compared to tumors with normal ESR1 gene status. Major variations in ER measured by ligand binding assay and IHC are observed within all ESR1 copy number subgroups and other mechanisms than gene copy number seem to contribute to the ER protein content in the tumors.

Citing Articles

Estrogen Receptor Alpha Mutations, Truncations, Heterodimers, and Therapies.

Hancock G, Gertz J, Jeselsohn R, Fanning S Endocrinology. 2024; 165(6).

PMID: 38643482 PMC: 11075793. DOI: 10.1210/endocr/bqae051.

Estrogen Receptor Alpha Gene Amplification Is an Independent Predictor of Long-Term Outcome in Postmenopausal Patients with Endocrine-Responsive Early Breast Cancer.

Singer C, Holst F, Steurer S, Burandt E, Lax S, Jakesz R Clin Cancer Res. 2022; 28(18):4112-4120.

PMID: 35920686 PMC: 9475247. DOI: 10.1158/1078-0432.CCR-21-4328.

Genomic copy number alterations as biomarkers for triple negative pregnancy-associated breast cancer.

Suelmann B, Rademaker A, van Dooijeweert C, van der Wall E, van Diest P, Moelans C Cell Oncol (Dordr). 2022; 45(4):591-600.

PMID: 35792986 PMC: 9424154. DOI: 10.1007/s13402-022-00685-6.

Compensatory Estrogen Signal Is Capable of DNA Repair in Antiestrogen-Responsive Cancer Cells via Activating Mutations.

Suba Z J Oncol. 2020; 2020:5418365.

PMID: 32774370 PMC: 7407016. DOI: 10.1155/2020/5418365.

Sparse quadratic classification rules via linear dimension reduction.

Gaynanova I, Wang T J Multivar Anal. 2019; 169:278-299.

PMID: 31105355 PMC: 6516858. DOI: 10.1016/j.jmva.2018.09.011.

References

Holst F, Stahl P, Ruiz C, Hellwinkel O, Jehan Z, Wendland M . Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer. Nat Genet. 2007; 39(5):655-60. DOI: 10.1038/ng2006. View

. Standards for the assessment of estrogen receptors in human breast cancer. Report of a workshop on September 29, 1972, at the Antoni van Leeuwenhoek-Huis, Amsterdam. Eur J Cancer (1965). 1973; 9(5):379-81. DOI: 10.1016/0014-2964(73)90055-8. View

Grabau D, Thorpe S, Knoop A, Vach W, Schroder H, Blichert-Toft M . Immunohistochemical assessment of oestrogen and progesterone receptors: correlations with the DCC method and clinical outcome in primary breast cancer patients. Breast. 2004; 9(4):208-17. DOI: 10.1054/brst.2000.0171. View

Olsen K, Knudsen H, Rasmussen B, Balslev E, Knoop A, Ejlertsen B . Amplification of HER2 and TOP2A and deletion of TOP2A genes in breast cancer investigated by new FISH probes. Acta Oncol. 2004; 43(1):35-42. DOI: 10.1080/02841860310019007. View

Allred D, Carlson R, Berry D, Burstein H, Edge S, Goldstein L . NCCN Task Force Report: Estrogen Receptor and Progesterone Receptor Testing in Breast Cancer by Immunohistochemistry. J Natl Compr Canc Netw. 2009; 7 Suppl 6:S1-S21. DOI: 10.6004/jnccn.2009.0079. View

Wolff A, Hammond M, Schwartz J, Hagerty K, Allred D, Cote R . American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2006; 25(1):118-45. DOI: 10.1200/JCO.2006.09.2775. View

Horlings H, Bergamaschi A, Nordgard S, Kim Y, Han W, Noh D . ESR1 gene amplification in breast cancer: a common phenomenon?. Nat Genet. 2008; 40(7):807-8. DOI: 10.1038/ng0708-807. View

Thorpe S, Christensen I, Rasmussen B, Rose C . Short recurrence-free survival associated with high oestrogen receptor levels in the natural history of postmenopausal, primary breast cancer. Eur J Cancer. 1993; 29A(7):971-7. DOI: 10.1016/s0959-8049(05)80204-7. View

Harvey J, Clark G, Osborne C, Allred D . Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol. 1999; 17(5):1474-81. DOI: 10.1200/JCO.1999.17.5.1474. View

10.

Talman M, Rasmussen B, Andersen J, Christensen I . Estrogen Receptor analyses in the Danish Breast Cancer Cooperative Group. History, methods, prognosis and clinical implications. Acta Oncol. 2008; 47(4):789-94. DOI: 10.1080/02841860801982741. View

11.

Tomita S, Zhang Z, Nakano M, Ibusuki M, Kawazoe T, Yamamoto Y . Estrogen receptor alpha gene ESR1 amplification may predict endocrine therapy responsiveness in breast cancer patients. Cancer Sci. 2009; 100(6):1012-7. PMC: 11159263. DOI: 10.1111/j.1349-7006.2009.01145.x. View

12.

Albertson D . Conflicting evidence on the frequency of ESR1 amplification in breast cancer. Nat Genet. 2008; 40(7):821-2. DOI: 10.1038/ng0708-821. View

13.

Henriksen K, Rasmussen B, Lykkesfeldt A, Moller S, Ejlertsen B, Mouridsen H . An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer. Acta Oncol. 2009; 48(4):522-31. DOI: 10.1080/02841860802676383. View

14.

BURKHARDT L, Grob T, Hermann I, Burandt E, Choschzick M, Janicke F . Gene amplification in ductal carcinoma in situ of the breast. Breast Cancer Res Treat. 2009; 123(3):757-65. DOI: 10.1007/s10549-009-0675-8. View

15.

Schuur E, Weigel R . Monoallelic amplification of estrogen receptor-alpha expression in breast cancer. Cancer Res. 2000; 60(10):2598-601. View

16.

Vincent-Salomon A, Raynal V, Lucchesi C, Gruel N, Delattre O . ESR1 gene amplification in breast cancer: a common phenomenon?. Nat Genet. 2008; 40(7):809. DOI: 10.1038/ng0708-809a. View

17.

Nielsen K, Ejlertsen B, Muller S, Moller S, Rasmussen B, Balslev E . Amplification of ESR1 may predict resistance to adjuvant tamoxifen in postmenopausal patients with hormone receptor positive breast cancer. Breast Cancer Res Treat. 2010; 127(2):345-55. DOI: 10.1007/s10549-010-0984-y. View

18.

Dunbier A, Anderson H, Ghazoui Z, Lopez-Knowles E, Pancholi S, Ribas R . ESR1 is co-expressed with closely adjacent uncharacterised genes spanning a breast cancer susceptibility locus at 6q25.1. PLoS Genet. 2011; 7(4):e1001382. PMC: 3084198. DOI: 10.1371/journal.pgen.1001382. View

19.

Ooi A, Inokuchi M, Harada S, Inazawa J, Tajiri R, Kitamura S . Gene amplification of ESR1 in breast cancers--fact or fiction? A fluorescence in situ hybridization and multiplex ligation-dependent probe amplification study. J Pathol. 2011; 227(1):8-16. DOI: 10.1002/path.3974. View

20.

Iwamoto T, Booser D, Valero V, Murray J, Koenig K, Esteva F . Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry. J Clin Oncol. 2012; 30(7):729-34. DOI: 10.1200/JCO.2011.36.2574. View